Gill Gauravpal S, Shailly Shikha, Chakrala Teja, Palicherla Anirudh, Ponna Pramod K, Alla Venkata Mahesh, Kanmanthareddy Arun
Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, United States of America.
Division of Nephrology, University of Michigan, Ann Arbor, MI, United States of America.
Cardiovasc Revasc Med. 2025 Jun;75:56-63. doi: 10.1016/j.carrev.2024.08.016. Epub 2024 Aug 22.
Chronic kidney disease (CKD) and end stage renal disease (ESRD) are associated with increased risk of bleeding events, including hemorrhagic stroke, and periprocedural and gastrointestinal bleeding among patients with atrial fibrillation who are on anticoagulation. Safety of percutaneous left atrial appendage occlusion (LAAO) among this patient population has been uncertain with studies showing contradictory results.
PubMed and Google Scholar databases were queried for studies comparing outcomes among patients with and without significant CKD, and with and without ESRD who underwent LAAO device implantation. Data on outcomes from the selected studies were extracted and analyzed using random effects model. Heterogeneity was assessed using I test.
Data from eleven studies with 61,724 patients with and without kidney disease were included in the final analyses. There was an increased risk of in-hospital mortality (OR 2.76, 95 % CI [1.15-6.64]; p = 0.02) and peri-procedural bleeding (1.51 [1.33-1.71]; p < 0.01) associated with kidney disease. There was no significant difference in risk of stroke (1.19 [0.70-2.03]; p = 0.53), pericardial effusion (1.22 [0.77-1.92]; p = 0.40), vascular complications (1.18 [0.92-1.52]; p = 0.20), or device related thrombus (1.13 [0.53-2.40]; p = 0.75).
This study shows an increased risk of complications among patients with kidney disease, who undergo LAAO device implantation. These findings suggest the need for studies with randomized control design specifically designed to compare outcomes with LAAO versus anticoagulation in the CKD and ESRD populations.
慢性肾脏病(CKD)和终末期肾病(ESRD)与出血事件风险增加相关,包括出血性卒中,以及接受抗凝治疗的心房颤动患者的围手术期出血和胃肠道出血。在这一患者群体中,经皮左心耳封堵术(LAAO)的安全性尚不确定,各项研究结果相互矛盾。
检索PubMed和谷歌学术数据库,查找比较接受LAAO装置植入的有或无严重CKD以及有或无ESRD患者结局的研究。使用随机效应模型提取并分析所选研究的结局数据。使用I检验评估异质性。
最终分析纳入了11项研究的数据,涉及61724例有或无肾脏疾病的患者。肾脏疾病与住院死亡率增加(比值比2.76,95%可信区间[1.15 - 6.64];p = 0.02)和围手术期出血(1.51[1.33 - 1.71];p < 0.01)风险相关。卒中风险(1.19[0.70 - 2.03];p = 0.53)、心包积液(1.22[0.77 - 1.92];p = 0.40)、血管并发症(1.18[0.92 - 1.52];p = 0.20)或装置相关血栓形成(1.13[0.53 - 2.40];p = 0.75)无显著差异。
本研究表明,接受LAAO装置植入的肾脏疾病患者并发症风险增加。这些发现提示,需要开展专门设计的随机对照研究,以比较CKD和ESRD人群中LAAO与抗凝治疗的结局。